The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease.
Scott D BringansKirsten E PetersTammy CaseyJason ItoRichard LipscombePublished in: Proteomes (2020)
PromarkerD is a proteomics derived test for predicting diabetic kidney disease that measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3. Antibodies against these proteins were developed and applied to a multiplexed immunoaffinity capture mass spectrometry assay. In parallel, and facilitating current clinical laboratory workflows, a standard ELISA was also developed to measure each protein. The performance characteristics of the two technology platforms were compared using a cohort of 100 samples, with PromarkerD test scores demonstrating a high correlation (R = 0.97). These technologies illustrate the potential for large scale, high throughput clinical applications of proteomics now and into the future.
Keyphrases
- mass spectrometry
- high throughput
- liquid chromatography
- gas chromatography
- capillary electrophoresis
- type diabetes
- single cell
- high performance liquid chromatography
- high resolution
- protein protein
- wound healing
- binding protein
- amino acid
- current status
- small molecule
- tandem mass spectrometry
- risk assessment
- monoclonal antibody
- human health
- simultaneous determination